Follow this page and receive
notifications about new suppliers
Gliclazide API Manufacturers
compare suppliers & get competitive offers
Date | Seller | Exporter country | Buyer | Importer country | Product | Quantity (KG) | Price per KG | Latest transactions |
---|---|---|---|---|---|---|---|---|
30-Sep-2024 | (Hidden) | India | TO AL-ARAF... | Bangladesh | PHARMACEUT... | 250 | $ @36$-7! | Check all data |
30-Sep-2024 | (Hidden) | India | N/A | Canada | PHARMACEUT... | 325 | $ @36$-7! | |
30-Sep-2024 | (Hidden) | India | N/A | Canada | PHARMACEUT... | 175 | $ @36$-7! |
Filters
Reset current filters
Type
Production region
Qualifications
Country of origin
Distributor
Produced in:
Established in: 2007
MOQ: -
Employees: 200+
GMP, WC, CEP, FDA, ISO Certificate
Arshine Group supplies more than 2,000 kinds of products
Arshine's marketing network has spread over more than 100 countries
+ 0
All certificates
Distributor
Produced in:
Established in: 2005
MOQ: -
Employees: 200+
Portfolio of over 2,000 APIs
Precise quality control
End-to-end global regulatory support
+ 0
All certificates
Producer
Produced in:
Established in: 2011
MOQ: 1 kg
Employees: 10+
Fast Response and Good Communication
Willingness To Start From Small
Flexible Payment Terms
+ 0
All certificates
Producer
Produced in:
Established in: 2021
MOQ: -
Employees: 19
API, Intermediates, Building Blocks, Impurities, Amino acids and Peptides
Small quantity APIs to commercial scale
GMP and USFDA certification based on quantity, order, assignment.
+ 0
All certificates
Distributor
Produced in:
Established in: 2019
MOQ: -
Employees: 50+
ISO 9001, SGS, Certificated supplier.
Audit available either on site or remote.
Professional One Stop Service for delivery to customers.
+ 0
All certificates
Distributor
Produced in:
Established in: 1994
MOQ: -
Employees: 50+
26+ years of distribution expertise with regulatory excellence
16 worldwide locations supplying high quality ingredients
All our manufacturer partners are cGMP complaint
+ 0
All certificates
Distributor
Produced in:
Established in: 1987
MOQ: 1 kg
Employees: 50+
ISO 9001:2015 & SGS audited supplier
One-stop CDMO Solutions for APl and Key intermediates
Specialized in APIs & Pharmaceutical Intermediates for 37 years
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
How does it work?
You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry
Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only
Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week
Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news
Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module
Looking for Gliclazide API 21187-98-4?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Gliclazide. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Gliclazide
- Synonyms:
- Gliclazida , Gliclazidum
- Cas Number:
- 21187-98-4
- DrugBank number:
- DB01120
- Unique Ingredient Identifier:
- G4PX8C4HKV
About Gliclazide
Want to know what Gliclazide is used for? Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It has been classified differently according to its drug properties in which based on its chemical structure, gliclazide is considered a first-generation sulfonylurea due to the structural presence of a sulfonamide group able to release a proton and the presence of one aromatic group. On the other hand, based on the pharmacological efficacy, gliclazide is considered a second-generation sulfonylurea which presents a higher potency and a shorter half-life Gliclazide belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating βcells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release.
Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic βcell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Gliclazide has been shown to decrease fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels (reflective of the last 8-10 weeks of glucose control). Gliclazide is extensively metabolized by the liver;its metabolites are excreted in both urine (60-70%) and feces (10-20%).
Ask the supplier for a certificate of analysis to find out more about the quality of Gliclazide.
Gliclazide is a type of Sulfonylureas
Sulfonylureas belong to a subcategory of pharmaceutical active ingredients known as antidiabetic agents. These compounds play a crucial role in managing type 2 diabetes, a metabolic disorder characterized by high blood sugar levels. Sulfonylureas work by stimulating the pancreas to produce more insulin, a hormone responsible for regulating blood glucose levels.
As pharmaceutical API, sulfonylureas are highly effective in lowering blood sugar levels by promoting insulin secretion and increasing the sensitivity of cells to insulin. This mechanism of action makes them valuable in the treatment of type 2 diabetes, especially when other measures such as diet and exercise have proven inadequate.
Sulfonylureas are widely prescribed due to their proven efficacy, oral administration convenience, and cost-effectiveness. They are available in various formulations, including tablets and extended-release formulations, allowing flexibility in dosing regimens. Additionally, their long-established presence in the market has resulted in a comprehensive understanding of their safety profile and potential side effects.
Some common sulfonylurea drugs include glipizide, glimepiride, and gliclazide. These compounds are often prescribed as part of a comprehensive treatment plan for type 2 diabetes, along with lifestyle modifications and other antidiabetic medications.
It is important to note that the use of sulfonylureas should be carefully monitored by healthcare professionals to ensure optimal blood sugar control and to minimize the risk of hypoglycemia, a potential side effect. Patients taking sulfonylureas should also be educated about the importance of regular blood glucose monitoring and adhering to prescribed dosages.
In conclusion, sulfonylureas represent an essential subcategory of pharmaceutical APIs used in the treatment of type 2 diabetes. Their mechanism of action, proven efficacy, and cost-effectiveness make them a valuable tool in managing this chronic metabolic condition. Healthcare professionals play a vital role in guiding the appropriate use of sulfonylureas to optimize patient outcomes and ensure safety.
Gliclazide (Sulfonylureas), classified under Anti-diabetics
Anti-diabetics, belonging to the pharmaceutical API (Active Pharmaceutical Ingredient) category, are a group of compounds designed to manage and treat diabetes mellitus, a chronic metabolic disorder characterized by high blood sugar levels. These medications play a vital role in controlling diabetes and preventing complications associated with the disease.
Anti-diabetics encompass a wide range of drug classes, including biguanides, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists. Each class works through different mechanisms to regulate blood sugar levels and improve insulin sensitivity.
Biguanides, such as metformin, reduce glucose production by the liver and enhance insulin sensitivity in peripheral tissues. Sulfonylureas, like glipizide, stimulate insulin secretion from pancreatic beta cells. Thiazolidinediones, including pioglitazone, improve insulin sensitivity in muscle and adipose tissues. DPP-4 inhibitors, such as sitagliptin, increase insulin release and inhibit glucagon secretion. SGLT2 inhibitors, like dapagliflozin, decrease renal glucose reabsorption, leading to increased urinary glucose excretion. GLP-1 receptor agonists, such as exenatide, enhance insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety.
These anti-diabetic APIs serve as the foundational ingredients for the formulation of various oral tablets, capsules, and injectable medications used in the treatment of diabetes. By targeting different aspects of glucose regulation, they help patients achieve and maintain optimal blood sugar levels, thus reducing the risk of diabetic complications, such as cardiovascular disease, neuropathy, and nephropathy.
It is crucial for healthcare professionals to prescribe and administer these anti-diabetic medications appropriately, considering factors like the patient's medical history, co-existing conditions, and potential drug interactions. Regular monitoring of blood glucose levels and close medical supervision are necessary to ensure effective diabetes management.
In conclusion, anti-diabetics form a critical category of pharmaceutical APIs used for the treatment of diabetes. These compounds, encompassing various drug classes, work through distinct mechanisms to regulate blood sugar levels and improve insulin sensitivity. By facilitating glucose control, anti-diabetic APIs help mitigate the risk of complications associated with diabetes mellitus, ultimately promoting better health outcomes for patients.
Gliclazide manufacturers | traders | suppliers
We have 12 companies offering Gliclazide produced in 5 different countries.
Get in contact with the supplier of your choice:
- Arshine Pharmaceutical Co., Limited from China, product country of origin China
- LGM Pharma from United States, product country of origin World
- Shandong Octagon Chemicals Limited from China, product country of origin China
- SETV Global from India, product country of origin India
- Aurora Industry Co., Ltd from China, product country of origin China
- Rochem International, Inc. from United States, product country of origin United States
- Sinoway industrial Co.,Ltd from China, product country of origin China
- Indoco Remedies from India, product country of origin India
- Kreative Organics from India, product country of origin India
- Cosma from Italy, product country of origin Italy
- Shandong Fangming from China, product country of origin China
- Edmond Pharma (Recipharm) from Italy, product country of origin Italy
Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.
You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.